OrbiMed Advisors LLC Reduces Stake in TELA Bio Inc
Express News | Orbimed Advisors LLC Reports 4.8% Stake in TELA Bio as of October 23, 2024 Vs 8.6% Stake as of September 27, 2024 - SEC Filing
Insider Purchase: CEO, COO, CFO, and CTO of TELA Bio (TELA) Buy Shares
Tela Bio Prices $40 Mln Public Offering At $2.25/share
Piper Sandler Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $8
Express News | TELA Bio Inc - Prices Public Offering of 12 Mln Shares at $2.25 Each
TELA Bio (TELA) Gets a Buy From Piper Sandler
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
12 Health Care Stocks Moving In Tuesday's After-Market Session
Express News | TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Express News | TELA Bio Inc - Expects Preliminary Q3 Revenue $19.0 Mln
Express News | TELA Bio Inc - in Q3 of 2024, Company Implemented Certain Cost-Cutting Measures
TELA Bio to Announce Third Quarter 2024 Financial Results
Demystifying TELA Bio: Insights From 6 Analyst Reviews
TELA Bio Price Target Maintained With a $12.00/Share by Canaccord Genuity
Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $8
Lake Street Reaffirms Their Buy Rating on TELA Bio (TELA)
CCORF Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $12
Orbimed Advisors LLC Reduces Stake in TELA Bio Inc
Piper Sandler Maintains TELA Bio(TELA.US) With Buy Rating, Cuts Target Price to $8
Piper Sandler analyst Matthew O'Brien maintains $TELA Bio(TELA.US)$ with a buy rating, and adjusts the target price from $10 to $8.According to TipRanks data, the analyst has a success rate of 50.6%